ImmuPharma (IMM) News Today GBX 1.78 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 19, 2024 | americanbankingnews.comImmuPharma (LON:IMM) Stock Passes Above 200-Day Moving Average of $1.90May 29, 2024 | lse.co.uk5x Long Qqq Share ChatMay 26, 2024 | lse.co.ukHsbc Bk.24 Share ChatMay 8, 2024 | msn.comInvestigational Drugs for Chronic Inflammatory Demyelinating PolyneuropathyMay 8, 2024 | msn.comLooking for top FTSE 100 value shares? Here’s one I’d buy without hesitationApril 2, 2024 | lse.co.ukImmupharma jumps amid new IP strategy for P140 technology platformMarch 25, 2024 | lse.co.ukIncanthera says first order from skincare deal doublesMarch 15, 2024 | msn.comSMALL CAP MOVERS: Versarien soars as advanced materials group offloads non-core assetsMarch 8, 2024 | finance.yahoo.comImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developmentsFebruary 24, 2024 | morningstar.comImmuPharma PLC IMMFebruary 21, 2024 | lse.co.ukUK government borrowing surplus rises in January from prior yearJanuary 17, 2024 | ca.finance.yahoo.comImmuPharma PLC (25I.SG)December 19, 2023 | lse.co.ukEARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrowsAugust 31, 2023 | lse.co.ukImmuPharma launches GBP2 million fund raise as interim loss narrowsAugust 31, 2023 | marketwatch.comImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working CapitalAugust 21, 2023 | lse.co.ukImmuPharma agrees 12 month extension to Incanthera warrant instrumentJune 27, 2023 | proactiveinvestors.comImmuPharma "absolutely delighted" to push on with new clinical trialJune 19, 2023 | proactiveinvestors.comImmuPharma presses on with next phase of Lupuzor clinical trialsMay 24, 2023 | proactiveinvestors.comImmuPharma "looking forward with quiet confidence" to FDA responseMay 18, 2023 | uk.investing.comFTSE 100 remains higher but off best with Wall Street indicated mixedMay 18, 2023 | marketwatch.comImmuPharma Shares Rise on Positive Guidance From US FDA for P140May 18, 2023 | proactiveinvestors.comImmuPharma shares jump 6.5% after FDA updateMay 18, 2023 | proactiveinvestors.comImmuPharma says CIDP trial will begin in the second half after meeting with US regulatorMay 12, 2023 | marketwatch.comSystemic Lupus Erythematous SLE Drug Market, Global Outlook and Forecast 2023-2029May 11, 2023 | proactiveinvestors.comImmuPharama eyes clinical trial progressMay 11, 2023 | proactiveinvestors.comImmuPharma eyes clinical trial progressApril 27, 2023 | proactiveinvestors.comImmuPharma "looking forward" to upcoming FDA meetingsApril 19, 2023 | proactiveinvestors.comImmuPharma partner gets FDA meeting dateApril 12, 2023 | marketwatch.comImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical ProgramApril 12, 2023 | proactiveinvestors.comImmuPharma rises 4% after it reveals headway with lead assetApril 12, 2023 | proactiveinvestors.comImmuPharma makes progress developing second indication for lead assetMarch 30, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Top Players By 2031March 27, 2023 | proactiveinvestors.comImmuPharma: US partner has submitted Lupuzor phase II/III trial protocolMarch 27, 2023 | marketwatch.comImmuPharma Shares Rise on Lupus Candidate FDA Trial SubmissionMarch 27, 2023 | proactiveinvestors.comImmuPharma: US partner submits Lupuzor phase II/III trial protocolMarch 6, 2023 | proactiveinvestors.comImmuPharma collaborates on potential 'radioactive bullet' to kill cancerFebruary 14, 2023 | marketwatch.comCutaneous Lupus Erythematosus (CLE) Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of SolutionsFebruary 8, 2023 | proactiveinvestors.comImmuPharma expects new Lupozor study to begin in H2 2023February 6, 2023 | lse.co.ukImmuPharma agrees study design with Avion for lupus programme LupuzorFebruary 6, 2023 | marketwatch.comImmuPharma Shares Rise After Lupuzor Trial ConfirmedFebruary 6, 2023 | proactiveinvestors.comImmuPharma partner agrees phase II/III clinical trial processJanuary 10, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Size 2023 Report Examines Latest Trends and Key Drivers Supporting Regional Outlook 2028December 22, 2022 | fxstreet.comUK data highlights oncoming recessionDecember 22, 2022 | marketwatch.comImmuPharma Shares Rise After Executives Waive Part of SalaryDecember 22, 2022 | proactiveinvestors.comImmuPharma says it has ‘clear objective’ to advance lupus treatment to next clinical trial in 2023November 11, 2022 | proactiveinvestors.comImmupharma’s US partner confirms support for lupus treatment and wants to expand collaborationNovember 11, 2022 | proactiveinvestors.comImmupharma’s US partner confirms support for lupus treatment, wants to expand collaborationOctober 13, 2022 | finance.yahoo.comAfter losing 57% in the past year, ImmuPharma plc (LON:IMM) institutional owners must be relieved by the recent gainOctober 6, 2022 | morningstar.co.ukTRADING UPDATES: ImmuPharma loss narrows; MetalNRG... - MorningstarOctober 6, 2022 | finance.yahoo.comImmuPharma plc (IMM.L) Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address “Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event. You can find out what they are by clicking here now. IMM Media Mentions By Week IMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.000.62▲Average Medical News Sentiment IMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼00▲IMM Articles Average Week Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AREC News C4XD News OBI News OPTI News HEMO News BVX News SNG News ROQ News DEST News VAL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:IMM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.